Determination of adriamycin, adriamycinol and their 7-deoxyaglycones in human serum by high-performance liquid chromatography
- PMID: 6520153
- DOI: 10.1016/s0378-4347(00)84698-8
Determination of adriamycin, adriamycinol and their 7-deoxyaglycones in human serum by high-performance liquid chromatography
Abstract
A reversed-phase isocratic high-performance liquid chromatographic assay is described for the measurement of adriamycin, adriamycinol and their 7-deoxyaglycones in human serum. The lower limit of detection in serum is 3 ng/ml for adriamycin and 1 ng/ml for adriamycinol and the 7-deoxyaglycones with coefficients of variation for k' of less than 5% throughout the day. An extraction technique for serum is described which is capable of an almost equal recovery (greater than 77%) of adriamycin, metabolites and daunorubicin (the internal standard) without interference from endogenous components of serum. Serum concentrations of metabolites 15 min after intravenous bolus administration of 40 mg/m2 adriamycin in two different patients were 26.5 and 16.6 ng/ml for adriamycinol; 109.8 and 5.8 ng/ml for the adriamycinol 7-deoxyaglycone and 21.4 and 17.1 ng/ml for the adriamycin 7-deoxyaglycone. A total of six metabolites of adriamycin were detected in the two patients using this methodology.
Similar articles
-
Determination of adriamycin and its fluorescent metabolites in human plasma by HPLC.Biomed Chromatogr. 1987 Feb;2(1):38-40. doi: 10.1002/bmc.1130020111. Biomed Chromatogr. 1987. PMID: 3508093
-
Method for the determination of 4'-deoxydoxorubicin, 4'-deoxydoxorubicinol and their 7-deoxyaglycones in human serum by high-performance liquid chromatography.J Chromatogr. 1985 Jun 14;341(2):401-9. doi: 10.1016/s0378-4347(00)84053-0. J Chromatogr. 1985. PMID: 4030989
-
Marked inter-patient variation in adriamycin biotransformation to 7-deoxyaglycones: evidence from metabolites identified in serum.Eur J Cancer Clin Oncol. 1986 Aug;22(8):991-1001. doi: 10.1016/0277-5379(86)90067-2. Eur J Cancer Clin Oncol. 1986. PMID: 3770056
-
Measurement of adriamycin (doxorubicin) and its metabolites in human plasma using reversed-phase high-performance liquid chromatography and fluorescence detection.J Chromatogr. 1979 Dec 1;164(4):471-8. doi: 10.1016/s0378-4347(00)81549-2. J Chromatogr. 1979. PMID: 541422
-
Reversed-phase liquid chromatographic determination of plasma levels of adriamycin and adriamycinol.J Chromatogr. 1979 Dec 1;164(4):479-86. doi: 10.1016/s0378-4347(00)81550-9. J Chromatogr. 1979. PMID: 541423
Cited by
-
Twenty-sixth annual general meeting of the British Association for Cancer Research (in conjunction with the European Organization for Research and Treatment for Cancer--Pharmacokinetics and Metabolism Group and the Drug Metabolism Group). March 24-27, 1985, Birmingham, U.K.Br J Cancer. 1985 Sep;52(3):409-67. doi: 10.1038/bjc.1985.210. Br J Cancer. 1985. PMID: 4041366 Free PMC article. No abstract available.
-
Niosome: A future of targeted drug delivery systems.J Adv Pharm Technol Res. 2010 Oct;1(4):374-80. doi: 10.4103/0110-5558.76435. J Adv Pharm Technol Res. 2010. PMID: 22247876 Free PMC article.
-
Antitumour activity and pharmacokinetics of niosome encapsulated adriamycin in monolayer, spheroid and xenograft.Br J Cancer. 1988 Oct;58(4):432-6. doi: 10.1038/bjc.1988.235. Br J Cancer. 1988. PMID: 3207598 Free PMC article.
-
Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer.Cancer Chemother Pharmacol. 1987;20(1):75-7. doi: 10.1007/BF00252964. Cancer Chemother Pharmacol. 1987. PMID: 3040287 Clinical Trial.
-
Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.Pharm Weekbl Sci. 1986 Apr 25;8(2):109-33. doi: 10.1007/BF02086146. Pharm Weekbl Sci. 1986. PMID: 3520474 Review.